Kalios
← Compounds

Injury & recovery · Daily shot

BPC-157

Gray market

Checked · 23 sources · 14 corrections on this page · No vendors · No affiliates · No one buys a word of it

3 human pilot studies

Limited Human Data · IV safety, bladder pain, knee pain · all from the same research group

Gray market · FDA panel said yes on July 23–24, 2026 — not legal yet

Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.

Not legal to compound — yet The FDA’s advisory committee recommended it on July 23–24, 2026. Recommended is not legal — nothing changes until rulemaking is finished. See every change →

Bottom line

Robust animal repair data (McGuire et al., 2025). Human proof is overdue — and criminally late.

Also called
  • Body Protection Compound-157
  • Pentadecapeptide
  • Bepecin (proposed INN)
  • PL 14736
Category
Peptide — Tissue Repair & Cytoprotection
Molecular Weight
1,419.53 Da
Sequence
15 amino acids (GEPPPGKPADDAGLV)
Half-life
<30 min (plasma)
Route (studied)
  • IV, intra-articular, intravesical (people)
  • IM, IP, oral, local injection (rats)
Route (sold)
SubQ vials (research chemical)
FDA Status
Not on 503A List. PCAC recommended 8-6 (Jul 2026)
Pipeline
  • Phase 1 after rotator cuff repair (University of Arkansas; not yet recruiting) (NCT07803250), primary completion est. Aug 2027
Published Articles
393 (1993–2024), once duplicates are removed from 544 records (Vasireddi et al., 2025)
Human Studies
3 small pilots; no Phase II registered
WADA Status
Banned (S0, 2022)
Evidence Strength
Preclinical: Strong
Human: Pilot only
Cost & Access
Research-only

Also for injury & recovery

The other four questions

What does it do? In animal studies it improved the healing of tendon, gut, nerve and skin injuries (Seiwerth et al., 2018; Sikiric et al., 2016) and increased new blood vessel growth (Hsieh et al., 2017).
Who uses it? Guys with stubborn tendon issues, post-surgery recovery, and functional-medicine clinics chasing faster healing.
Does the evidence hold up? 544 search hits, 393 once duplicates are removed (Vasireddi et al., 2025). Almost all rats and mice (Józwiak et al., 2025). Three tiny human pilots (McGuire et al., 2025). No Phase II trial is registered; the developer's only registration is a Phase I with no results posted (NCT02637284). The gap between "lab magic" and "proven in people" is still huge.
Bottom line? Robust animal repair data (McGuire et al., 2025). Human proof is overdue — and criminally late.

Dosing from the Literature

Published for tendon and gut repair: rat doses (10 mcg/kg; Staresinic et al., 2003); the three tiny human pilots looked at IV safety, bladder pain and knee pain instead. Not published: any human dose-finding trial.

The human figures below are what clinic protocols and online guides describe; no published trial has tested them. The animal figures come from the studies cited. This is not medical advice.

RouteDose RangeFrequencyNotes
Subcutaneous250–500 mcg1–2x dailyWhat clinic protocols describe: injected near the injury, with injection sites rotated. Clinic pages also describe IM injection for deeper musculoskeletal injuries.
Oral250–500 mcg1–2x dailyWhat clinic pages and online guides describe, on an empty stomach about 30 minutes before meals. In animal gut-injury models it worked by mouth as well as by injection (Seiwerth et al., 2018), and it is stable in human gastric juice (Sikiric et al., 2011).
Animal reference10 mcg/kgDailyRats with cut Achilles tendons: 10 mcg/kg i.p. once daily, the highest of three doses tested with 10 ng/kg and 10 pg/kg (Staresinic et al., 2003; Krivic et al., 2006). Most musculoskeletal animal studies gave it once daily (McGuire et al., 2025). Animal toxicity studies found no acute lethal or toxic dose from 6 mcg/kg to 20 mg/kg (Vasireddi et al., 2025).
Cycle length4–8 weeks—What clinic protocols describe: daily doses, then 2–4 weeks off. One clinic lists 4–6 weeks for acute injuries and 6–8 for chronic pain or inflammation.
Dosing Disclaimer

No controlled clinical trial has established a human dose. The figures above are for educational reference only. Always work with a licensed healthcare provider.

→ Calculator — vial-to-syringe math

What It Is

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — derived from a naturally occurring protein found in human gastric juice. The "BPC" stands for Body Protection Compound. It was first isolated and characterized by researchers at the University of Zagreb in the early 1990s under the direction of Predrag Sikiric, who has led BPC-157 research for over three decades.

Unlike most peptides in the optimization space, BPC-157 is remarkably stable in human gastric juice. This means it can be administered orally and still retain biological activity — an unusual property for a peptide that is typically destroyed by digestive enzymes. This gastric stability is one reason it has generated significant research interest, particularly for gastrointestinal applications, and it is the single structural feature that separates BPC-157 from essentially every other injection-only tissue-repair peptide.

A 2025 systematic review by Vasireddi et al. in the HSS Journal identified 544 records on BPC-157 from 1993 to 2024, 393 once duplicates were removed, making it one of the most extensively studied research peptides. PubMed now indexes over 190 BPC-157 results, with research output roughly quadrupling since 2020. Despite that volume, only three published human pilot studies exist. The gap between preclinical enthusiasm and clinical evidence is the defining feature of BPC-157's present evidence profile, and understanding that gap is the most important context for anyone considering its use.

BPC-157 also sits at the center of the 2026 peptide-regulatory story. In late February 2026 the HHS secretary said on a podcast that he expected FDA to change the status of “about 14” peptides (NPR, March 31, 2026); those were public remarks, not a rule. On April 15, 2026 FDA gave notice that 12 peptides, BPC-157 among them, would leave Category 2 because their nominations had been withdrawn, removed them on April 22, 2026 (FDA notice April 15, 2026), and took them to the Pharmacy Compounding Advisory Committee. On July 23, 2026 the committee voted 8-6 with 1 abstention to recommend BPC-157 (free base and acetate forms) for inclusion on the 503A Bulks List. FDA staff had recommended against. The vote is advisory: FDA has not initiated rulemaking, and BPC-157 cannot yet be legally compounded in the US.

Mechanism of Action

BPC-157 is described as pleiotropic (having many effects at once), acting through multiple interconnected pathways in cell and animal studies (McGuire et al., 2025; PMID 40789979). In animal models it has been reported to aid healing in tendon, gut, nerve, bone, muscle and blood-vessel lining (McGuire et al., 2025; Sikiric et al., 2011).

  • VEGFR2-Akt-eNOS pathway (angiogenesis) — In rats with an ischemic hind limb and in cultured human endothelial cells, BPC-157 raised vascular endothelial growth factor receptor-2 (VEGFR2) expression, promoted its internalization and activated the downstream VEGFR2-Akt-eNOS pathway; vessel numbers and blood-flow recovery rose in the rats' limbs (Hsieh et al., 2017; PMID 27847966). In the endothelial cells VEGF-A itself did not rise, so the authors tie the effect to the receptor rather than to more VEGF (Hsieh et al., 2017); other rat studies report higher VEGF expression (Vasireddi et al., 2025; PMID 40756949).
  • Src-Caveolin-1-eNOS pathway (nitric oxide production) — Research from Chang Gung University in Taiwan, independent of the Zagreb group, found that BPC-157 relaxed isolated rat aorta in a concentration-dependent way that depended on the endothelium and nitric oxide, and that in human endothelial cells it increased phosphorylation of Src, Caveolin-1 and eNOS and loosened the inhibitory Cav-1–eNOS binding (Hsieh et al., 2020; PMID 33051481). The authors conclude that BPC-157 activates eNOS through several routes at once, VEGFR2 among them (Hsieh et al., 2020).
  • FAK-paxillin pathway (cell migration) — In cultured rat tendon fibroblasts (cells that build collagen), BPC-157 raised FAK and paxillin expression, and the cells migrated more and survived stress better; a 2025 systematic review reads this as activation of the FAK-paxillin pathway, important in cell adhesion, migration, proliferation and survival (Vasireddi et al., 2025; PMID 40756949).
  • Growth hormone receptor upregulation — In tendon fibroblasts cultured from rat Achilles tendon, BPC-157 raised growth hormone receptor levels (mRNA and protein) in a dose- and time-dependent way, and adding growth hormone then increased the cells' proliferation, with JAK2 activation; the authors propose this may contribute to tendon healing (Chang et al., 2014; PMID 25415472).
  • Nitric oxide system modulation (bidirectional) — In animal studies BPC-157 counteracted harmful effects of the NO-synthase blocker L-NAME and some effects of the NO precursor L-arginine (Józwiak et al., 2025; PMID 40005999), including effects on blood pressure (Sikiric et al., 2016; PMID 27138887). In a rat stroke model it raised brain mRNA for endothelial NOS (Nos3) and lowered inducible NOS (Nos2) (Vukojevic et al., 2022; PMID 34380875).
  • ERK1/2 signaling — In endothelial cell studies, BPC-157 increased activity of the extracellular signal-regulated kinase (ERK1/2) pathway along with cell proliferation, migration and tube formation, and blocking ERK abolished those effects; in rodent alkali-burn wounds, faster healing coincided with higher ERK1/2 activity (McGuire et al., 2025; PMID 40789979).
  • Dopamine and serotonin system interaction — Rodent studies show BPC-157 influences the dopaminergic (related to dopamine signaling) and serotonergic (related to serotonin signaling) systems, counteracting behavioral disturbances caused by over-stimulating or damaging them (Sikiric et al., 2016; PMID 27138887). It interacts with the dopamine, glutamate, serotonin and nitric-oxide systems in rodent models — including models using MK-801, an NMDA-receptor antagonist — which the review presents as the basis for its reported CNS effects (Vukojevic et al., 2022).
  • GI cytoprotection — In animal studies reviewed by the Zagreb group, BPC-157 showed cytoprotective (cell-protecting) effects along the gastrointestinal tract, counteracting alcohol- and NSAID-induced lesions, and it reduced esophagitis in rats (Sikiric et al., 2011; PMID 21548867). Gastric mucosal blood flow restoration reaches approximately 90% of baseline within 24 hours in NSAID-induced ulcer models (Sikiric et al., 2011).
  • Vascular occlusion counteraction — The Zagreb group reports that in rat models of major vessel occlusion, BPC-157 rapidly activated alternative bypass pathways around the blocked vessel, an effect it ties to its "cytoprotection" concept (Vukojevic et al., 2022; PMID 34380875).

What the Research Shows

BPC-157 has been studied across a wide range of injury and disease states in animal models. The 2025 Vasireddi systematic review found 393 articles once duplicates were removed (544 records in all) and included 36 meeting full criteria — 35 preclinical and 1 clinical. The preclinical evidence is large and consistent, but almost entirely from rodent models.

  • Tendon and ligament repair — Multiple rat studies show accelerated healing of Achilles tendon transections, MCL injuries, and muscle crush injuries. Tendon-to-bone healing was improved in rotator cuff and Achilles detachment models, and BPC-157 opposed the healing-aggravation caused by concurrent corticosteroids (Staresinic et al., 2003; Krivic et al., 2006). In vitro, BPC-157 improved tendon fibroblast survival under stress, increased cell migration indices, cell proliferation, and growth hormone receptor expression.
  • Gut healing — The most robust area of BPC-157 research. Demonstrated protection against inflammatory bowel disease models, NSAID-induced GI lesions, gastric ulcers, esophageal reflux damage, intestinal anastomosis healing, and fistula closure in rats. Acts on the brain-gut axis, the subject of the 2016 review (Sikiric et al., 2011; 2016).
  • Wound healing — Accelerated closure of incisional and excisional wounds in rat models, including diabetic wound healing where healing is typically impaired. Higher numbers of collagen, reticulin, and blood vessel development compared to control groups.
  • Neuroprotection — Protection against peripheral nerve damage, dopaminergic neurotoxicity, cuprizone-induced demyelination, and traumatic brain injury in rodent models. BPC-157 also interacts with the glutamate system, including in rodent models using MK-801, an NMDA-receptor antagonist (Vukojevic et al., 2022).
  • Bone healing — Improved osteogenic activity and fracture healing in rabbit segmental bone defect models and tendon-to-bone healing in rats.
  • Vascular protection — Counteracts major vessel occlusion syndromes by rapidly activating collateral blood vessel pathways. Shown effective in models of mesenteric vessel occlusion and in glaucoma models induced by episcleral vein cauterization.
  • Organ protection — Cytoprotective effects observed across liver, kidney, heart, and brain tissue in various toxicity models, including protection against corticosteroid-induced muscle damage and lower-extremity ischemia-reperfusion-induced distant organ injury.
Critical Context — Research Independence

Over 80% of the ~190 PubMed-indexed BPC-157 articles list P. Sikiric or S. Seiwerth (University of Zagreb) as first or senior author. Independent laboratories have contributed only a handful of in vitro or short-term rodent studies. The most significant independent contribution is the Src-Caveolin-1-eNOS pathway work from Chang Gung University in Taiwan, and the Xu et al. preclinical safety evaluation in mice, rats, rabbits, and dogs. Heavy reliance on a single research group restricts generalizability and increases the risk of confirmation bias.

Human Data

As of April 2026, three published human pilot studies exist, all from the same research group:

  • Intravenous safety pilot (Lee & Burgess, 2025; PMID 40131143) — IV BPC-157 administered at 10 mg followed by 20 mg the next day in two healthy adults. No adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers. Plasma clearance within 24 hours. N=2 is descriptive, not inferential.
  • Interstitial cystitis pilot (Lee, Walker & Ayadi, 2024) — Intravesical BPC-157 in 12 women with moderate-to-severe interstitial cystitis who had failed first-line therapy (pentosan polysulfate). Reported 80–100% symptom resolution at 6 weeks. No control group, no blinding, small sample, single clinic.
  • Chronic knee pain retrospective (Lee & Padgett, 2021) — 16 patients receiving intraarticular BPC-157 (alone or with thymosin beta-4) for various knee pain etiologies. 14 of 16 reported subjective improvement at 6–12 months recall. Uncontrolled, retrospective, subjective endpoint with heavy recall bias risk.

No Phase II trial of BPC-157 is registered on ClinicalTrials.gov; the only registration from its developer is a Phase I safety and pharmacokinetics trial (PCO-02, NCT02637284), with no results posted. No large-scale randomized controlled trials have been completed for any indication.

Outside of these three pilots, the vast majority of reports about human use are anecdotal: practitioner case reports, podcast interviews, and community forums. These are not the same as controlled evidence.

Reconstitution & Storage

Sellers list BPC-157 as a lyophilized (freeze-dried) powder, in vials of 5 mg, 10 mg and other sizes.

Vial SizeBAC WaterConcentration250 mcg Dose500 mcg Dose
5 mg2 mL2,500 mcg/mL10 units (0.10 mL)20 units (0.20 mL)
10 mg2 mL5,000 mcg/mL5 units (0.05 mL)10 units (0.10 mL)
  • Reconstitution — Seller reconstitution guides describe adding the bacteriostatic water gently down the inside wall of the vial and swirling, rather than shaking, until the solution is clear.
  • Storage — Seller and guide listings disagree. For the unmixed powder they range from 3 weeks at room temperature (with long-term storage frozen below −18°C) to 6–12 months; for the mixed solution, refrigeration at 2–8°C for anywhere from 2–7 days to 28–30 days. They agree on avoiding repeated freezing and thawing.
  • Inspection — Online guides describe discarding a solution that turns cloudy, changes color or shows particles.

→ Calculator — vial-to-syringe math

Side Effects & Risks

Important

Animal safety studies found no adverse effects across several organ systems (Vasireddi et al., 2025). Human data are extremely limited (McGuire et al., 2025). What this means for a given person is a question for a licensed healthcare provider.

BPC-157 has a generally favorable safety profile in the available preclinical research (Vasireddi et al., 2025), but human data remain extremely limited (McGuire et al., 2025):

  • Reported side effects — Anonymous online users report injection-site pain and swelling, joint pain, anxiety, panic attacks, heart palpitations, insomnia, drowsiness, weakness, fatigue, loss of appetite, depression and anhedonia, a loss of pleasure (Vasireddi et al., 2025). These are anonymous reports, not trial data. The 2025 IV safety pilot (n=2) reported no adverse effects at doses up to 20 mg (Lee & Burgess, 2025); the 2024 interstitial cystitis pilot (n=12) reported no adverse events (Lee et al., 2024).
  • Growth factor / tumor concerns — Because BPC-157 raised VEGFR2 and new blood vessel growth (angiogenesis) in animal and cell studies (Hsieh et al., 2017), there is a theoretical concern about promoting growth in existing tumors or precancerous tissue. The evidence a 2025 review cites against that concern, that BPC-157 slowed cell growth and VEGF signaling, comes from the Zagreb group, including a 2004 study in a human melanoma cell line (McGuire et al., 2025). The only cancer-related study another 2025 review found was in mice with implanted colon cancer cells: BPC-157 improved body weight, and tumor volume was lower but not significantly (Józwiak et al., 2025). Independent reviewers (Józwiak et al., 2025; McGuire et al., 2025) explicitly flag pro-angiogenic signaling as a plausible tumor-promoting hazard that has not been adequately studied.
  • WADA banned substance — Banned by the World Anti-Doping Agency in 2022 under category S0 (non-approved substances). USADA has issued explicit advisories against use. Detection methods (UHPLC-HRMS) are now established.
  • Purity and contamination — Products sold as BPC-157 are unregulated for quality and safety, and a 2025 systematic review notes that adverse effects are possible from unregulated manufacturing and contamination (Vasireddi et al., 2025).
  • Drug interactions — Unstudied in humans: because BPC-157 acts mainly on the nitric oxide (NO) system, a 2025 review calls for study of its interactions with drugs that act on NO pathways, such as aspirin, and flags people with cardiovascular disease or its risk factors for particular care (Józwiak et al., 2025). In rats, a corticosteroid (6α-methylprednisolone) worsened tendon-to-bone healing, and BPC-157 reduced that worsening (Krivic et al., 2006).
  • No identified lethal dose — Preclinical toxicology in mice, rats, rabbits, and dogs (Xu et al., 2020) identified no lethal dose and no serious toxicity; a single 20 mg/kg dose caused no deaths in rats (Józwiak et al., 2025). Human safety remains unknown (Vasireddi et al., 2025).

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for BPC-157. The intravenous pilot measured heart, liver, kidney and thyroid markers, blood glucose and vital signs before and after each infusion, in two adults (Lee & Burgess, 2025).

Commonly Stacked With

TB-500

Sold with BPC-157 as the "Wolverine Stack." One rat study tested the two together after Achilles tendon repair: the pair did no better than either alone (Biçer et al., 2026); no published study has given the pair to people.

Tested together in people: none published · Read the receipt →

Thymosin Beta-4

The full protein TB-500 copies a short piece of (see its page). In the only published human report of BPC-157 with it, 4 of 16 knee-pain patients received the two together, and 3 of the 4 reported relief, in an uncontrolled, retrospective series (Lee & Padgett, 2021).

Tested together in people: 1 chart review, 4 patients (2021) (Lee & Padgett, 2021) · Read the receipt →

GHK-Cu

Sellers combine it with BPC-157 and TB-500 in one pre-blended vial, sold as the GLOW Stack (GHK-Cu + BPC-157 + TB-500) and marketed for collagen and tissue repair.

Tested together in people: none published · Read the receipt →

KPV

A tripeptide sold as an anti-inflammatory. Sellers add it to the GLOW blend in one pre-blended vial, sold as the KLOW Stack (KPV + GHK-Cu + BPC-157 + TB-500).

Tested together in people: none published · Read the receipt →

CJC-1295 + Ipamorelin

Growth hormone secretagogue pair. Online peptide guides list BPC-157 with CJC-1295 and ipamorelin among common stacks for athletic recovery. No published study tests the combination; in cultured rat tendon cells, BPC-157 raised growth hormone receptor levels, and added growth hormone then increased the cells' proliferation (Chang et al., 2014).

Tested together in people: none published · Read the receipt →

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

PCAC vote — July 23, 2026: 8 yes, 6 no, 1 abstain. The FDA Pharmacy Compounding Advisory Committee recommended BPC-157 (free base and acetate forms) for inclusion on the Section 503A Bulks List; FDA staff had recommended against. A recommendation is advisory — BPC-157 is not yet legal to compound. Full tracker →
Current Status — September 2026

BPC-157 was removed from Category 2 on April 22, 2026 (FDA notice April 15, 2026). PCAC recommended it on July 23–24, 2026. Rulemaking pending — not legal to compound today. On July 23, 2026 the committee voted 8 yes, 6 no, 1 abstention to recommend BPC-157 (both free base and acetate forms) for inclusion on the Section 503A Bulks List. FDA staff had recommended against inclusion.

A PCAC recommendation is advisory. FDA has not initiated notice-and-comment rulemaking to add BPC-157 to the 503A Bulks List, and no rulemaking deadline has been announced. Until a final rule takes effect, BPC-157 is not on the 503A Bulks List and cannot be legally compounded from bulk drug substance under 503A.

BPC-157 is not approved by the FDA for any therapeutic indication. It is classified as a research chemical. It was banned by WADA in 2022 under S0 (non-approved substances). The proposed INN "Bepecin" was submitted by researchers, signaling intent for eventual pharmaceutical development. A Phase I safety/PK registration from its developer (NCT02637284) is the only such record on ClinicalTrials.gov; no results were posted.

Cost & Access

BPC-157 is not approved for human use. It is available through research suppliers for laboratory research purposes only.

U.S. compounding pharmacies cannot legally compound BPC-157 from bulk drug substance under current FDA rules — BPC-157 is not on the Section 503A Bulks List. The July 2026 PCAC vote is a recommendation for future inclusion, not a rule change. Online research-chemical channels list BPC-157 at variable prices and quality, with purity varying substantially between vendors.

Pricing and availability vary by provider, location, and prescription status. Kalios does not sell compounds.

References

  1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 records identified, 393 once duplicates were removed; 36 studies included.)
  2. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979.
  3. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999.
  4. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143.
  5. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560.
  6. Lee E, Padgett B. Intra-articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435.
  7. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
  8. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800.
  9. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966.
  10. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481. (Independent Taiwan data — the most important non-Zagreb mechanistic paper.)
  11. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMID: 25415472.
  12. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
  13. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442.
  14. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887.
  15. Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875.
  16. Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID: 32334036. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identified.)
  17. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides — An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy. 2025;41(2):150-152. DOI: 10.1016/j.arthro.2024.09.005.
  18. USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org.
  19. ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial (PharmaCotherapia). NCT02637284.
  20. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025.
  21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
  22. Stone W. The wellness world is eager for RFK Jr.’s promised move on peptides. NPR, March 31, 2026. npr.org/2026/03/31/nx-s1-5768206/peptides-rfk-fda-compounding-pharmacies. Read October 3, 2026. (The HHS secretary’s late-February podcast remarks, “about 14” peptides; reported, not a rule.)
  23. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID: 42542926. DOI: 10.52312/jdrs.2026.2951.

Also for injury & recovery

Tested together in people

See every change to this page → · Status now →

Checked 18 Oct 2026